Drug-induced interstitial lung disease: a narrative review of a clinical conundrum
Expert Rev Respir Med. 2024 Jan-Feb;18(1-2):23-39. doi: 10.1080/17476348.2024.2329612. Epub 2024 Mar 19.ABSTRACTINTRODUCTION: Drug-induced interstitial lung disease (DI-ILD) is increasing in incidence, due to the use of many new drugs across a broad range of cancers and chronic inflammatory diseases. The presentation and onset of DI-ILD are variable even for the same drug across different individuals. Clinical suspicion is essential for identifying these conditions, with timely drug cessation an important determinant of outcomes.AREAS COVERED: This review provides a comprehensive and up-to-date summary of epidemiology, ris...
Source: Expert Review of Respiratory Medicine - March 19, 2024 Category: Respiratory Medicine Authors: Megan Harrison Grace Kavanagh Tamera J Corte Lauren K Troy Source Type: research
Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Childrens Cancer Group Multicentre Trial, JPLSG B-NHL-20)
Introduction
Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome Malin B (LMB) chemotherapy markedly prolongs event-free survival and overall survival in high-risk patients, the benefit of rituximab in good-risk patients remains to be elucidated. This clinical trial will examine whether the addition of rituximab eliminates anthracyclines in good-risk patients without compromising treatment o...
Source: BMJ Open - March 19, 2024 Category: General Medicine Authors: Sekimizu, M., Fukano, R., Koga, Y., Mitsui, T., Fujita, N., Mori, T., Hori, D., Tanaka, M., Ohki, K., Iwafuchi, H., Nakazawa, A., Mori, T., Kobayashi, R., Hashimoto, H., M. Saito, A., Kamei, M., on behalf of Lymphoma Committee of Japan Childrens Cancer Gr Tags: Open access, Haematology (incl blood transfusion) Source Type: research
